“There's a lot that urologists can pick up on how to better interact with their patients,” says David King Keller, PhD, of Active Surveillance Patients International.
In this video, David King Keller, PhD, of Active Surveillance Patients International (www.aspatients.org), discusses the organization’s upcoming webinar, “The Leading Edge of Active Surveillance for Patients and Urologists,” featuring Eric Klein, MD, on July 31.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.